SCHEMBL30945237

SCHEMBL30945237

CS(=O)(=O)c1ccc(Br)cc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
KDM1A O60341 2/20 0.40
ABCB11 O95342 1/20 0.40
TRPV4 Q9HBA0 1/20 0.39
KIF11 P52732 1/20 0.39
CCR2 P41597 2/20 0.39
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
CA5A P35218 2/20 0.39
CA9 Q16790 2/20 0.39
HSD11B1 P28845 2/20 0.38
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
CA12 O43570 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709661 1.00 PFKFB3 (0.41) PFKFB3PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL29217890 0.85 KIF11 (0.42) KDM1AKIF11CCR2CA1CA2
SCHEMBL4194854 0.82 DDR1 (0.46) PFKFB3KDM1ATRPV4CCR2CA1
SCHEMBL14100608 0.81 PFKFB3 (0.41) PFKFB3KDM1ATRPV4CA1CA2
SCHEMBL1541130 0.81 CA2 (0.53) PFKFB3KDM1AABCB11TRPV4KIF11
SCHEMBL29744331 0.81 CA2 (0.53) PFKFB3KDM1AABCB11TRPV4KIF11
SCHEMBL695564 0.81 TRPV4 (0.58) PFKFB3KDM1ATRPV4CA1CA2
SCHEMBL10296146 0.81 PFKFB3 (0.41) PFKFB3KDM1ATRPV4CA1CA2
SCHEMBL29843259 0.81 TRPV4 (0.58) PFKFB3KDM1ATRPV4CA1CA2
SCHEMBL28766850 0.81 CCR2 (0.41) CCR2CA1CA2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
US-20240383904-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-21 US disclosed
US-20240199587-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199587-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP4B1 PFKFB3 3736/4885PIK3CD 3509/4885PIK3CA 2682/4885
US-20240383904-A1 HETEROCYCLIC COMPOUNDS MAGI3, MAG, MAGT1 PFKFB3 3896/4885PIK3CD 1627/4885PIK3CA 1157/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 PFKFB3 4435/4885PIK3CD 3728/4885PIK3CA 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.